CMPX -35%
좋은 데이터를 공개한 바이킹 테라퓨틱스
Data from the VK2735-102 maintenance study also demonstrated a 22% weight loss for injectable over 33 weeks and its potential in maintaining weight loss effects after switching from a weekly regimen in the induction phase to less frequent regimens in the maintenance phase.
vs
진행성담도암에서 OS가 통계적 유의성확보 실패하며 추가 임상 권고
https://www.globenewswire.com/news-release/2026/09/22/3366335/0/en/compass-therapeutics-provides-regulatory-update-on-tovecimig-in-biliary-tract-cancer-following-fda-feedback.html